Multigene delivery and expression systems are emerging as key technologies for many applications in contemporary biology. We have developed new methods for multigene delivery and expression in eukaryotic hosts for a variety of applications, including production of protein complexes for structural biology and drug development, provision of multicomponent protein biologics, and cell-based assays. We implemented tandem recombineering to facilitate rapid generation of multicomponent gene expression constructs for efficient transformation of mammalian cells, resulting in homogenous cell populations. Analysis of multiple parameters in living cells may require co-expression of fluorescently tagged sensors simultaneously in a single cell, at defined and ideally controlled ratios. Our method enables such applications by overcoming currently limiting challenges. Here, we review recent multigene delivery and expression strategies and their exploitation in mammalian cells. We discuss applications in drug discovery assays, interaction studies, and biologics production, which may benefit in the future from our novel approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bies.201100109 | DOI Listing |
Int J Mol Sci
December 2024
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 159/2, Prospect 100 let Vladivostoku, Vladivostok 690022, Russia.
sp. KMM 8419 (=CB1-14) is a Gram-negative bacterium isolated from a food-net mucus sample of marine polychaete collected in the Sea of Japan. Here, we report the structure and biosynthetic gene cluster of the capsular polysaccharide (CPS) from strain KMM 8419.
View Article and Find Full Text PDFNanotheranostics
November 2024
School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore 639798, Singapore.
[This corrects the article DOI: 10.7150/ntno.27308.
View Article and Find Full Text PDFViruses
September 2024
School of Biochemistry, University of Bristol, 1 Tankard's Close, Bristol BS8 1TD, UK.
J Pers Med
September 2024
Biomedical Ethics Research Program, Mayo Clinic, Rochester, MN 55905, USA.
Ann Surg Oncol
January 2025
Division of Research, Oakland, Kaiser Permanente, Oakland, USA.
Background: This study evaluated a new mainstream genetic testing pathway for hereditary cancer, with expanded eligibility for early-stage breast cancer patients.
Methods: The study compared multigene panel (62 genes) germline testing uptake and results for breast cancer patients at 4 pilot sites (n = 502 patients) and 10 non-pilot sites (n = 1792 patients) within Kaiser Permanente Northern California from December 2020, to June 2021. At the pilot sites, breast care coordinators (BCCs) offered and consented patients for testing, with eligibility expanded to include all patients age 65 years or younger.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!